Home > Publications Database > Synthesis, structural characterization and study of antioxidant and anti-PrPSc properties of flavonoids and their rhenium(I)-tricarbonyl complexes. > print

001     256473
005     20240322115508.0
024 7 _ |a 10.1007/s00775-022-01986-9
|2 doi
024 7 _ |a pmid:36695886
|2 pmid
024 7 _ |a pmc:PMC9981504
|2 pmc
024 7 _ |a 0949-8257
|2 ISSN
024 7 _ |a 1432-1327
|2 ISSN
024 7 _ |a altmetric:141862152
|2 altmetric
037 _ _ |a DZNE-2023-00335
041 _ _ |a English
100 1 _ |a Glykofridi, Pigi
|b 0
245 _ _ |a Synthesis, structural characterization and study of antioxidant and anti-PrPSc properties of flavonoids and their rhenium(I)-tricarbonyl complexes.
260 _ _ |a New York
|c 2023
|b Springer
336 7 _ |a article
|2 DRIVER
336 7 _ |a Output Types/Journal article
|2 DataCite
336 7 _ |a Journal Article
|b journal
|m journal
|0 PUB:(DE-HGF)16
|s 1711017907_32502
|2 PUB:(DE-HGF)
336 7 _ |a ARTICLE
|2 BibTeX
336 7 _ |a JOURNAL_ARTICLE
|2 ORCID
336 7 _ |a Journal Article
|0 0
|2 EndNote
500 _ _ |a CC BY
520 _ _ |a This study aims at the synthesis and initial biological evaluation of novel rhenium-tricarbonyl complexes of 3,3',4',5,7-pentahydroxyflavone (quercetin), 3,7,4΄-trihydroxyflavone (resokaempferol), 5,7-dihydroxyflavone (chrysin) and 4΄,5,7-trihydroxyflavonone (naringenin) as neuroprotective and anti-PrP agents. Resokaempferol was synthesized from 2,2΄,4-trihydroxychalcone by H2O2/NaOH. The rhenium-tricarbonyl complexes of the type fac-[Re(CO)3(Fl)(sol)] were synthesized by reacting the precursor fac-[Re(CO)3(sol)3]+ with an equimolar amount of the flavonoids (Fl) quercetin, resokaempferol, chrysin and naringenin and the solvent (sol) was methanol or water. The respective Re-flavonoid complexes were purified by semi-preparative HPLC and characterized by spectroscopic methods. Furthermore, the structure of Re-chrysin was elucidated by X-ray crystallography. Initial screening of the neuroprotective properties of these compounds included the in vitro assessment of the antioxidant properties by the DPPH assay as well as the anti-lipid peroxidation of linoleic acid in the presence of AAPH and their ability to inhibit soybean lipoxygenase. From the above studies, it was concluded that the complexes' properties are mainly correlated with the structural characteristics and the presence of the flavonoids. The flavonoids and their respective Re-complexes were also tested in vitro for their ability to inhibit the formation and aggregation of the amyloid-like abnormal prion protein, PrPSc, by employing the real-time quaking-induced conversion assay with recombinant PrP seeded with cerebrospinal fluid from patients with Creutzfeldt-Jakob disease. All the compounds blocked de novo abnormal PrP formation and aggregation.
536 _ _ |a 353 - Clinical and Health Care Research (POF4-353)
|0 G:(DE-HGF)POF4-353
|c POF4-353
|f POF IV
|x 0
536 _ _ |a 352 - Disease Mechanisms (POF4-352)
|0 G:(DE-HGF)POF4-352
|c POF4-352
|f POF IV
|x 1
588 _ _ |a Dataset connected to CrossRef, PubMed, , Journals: pub.dzne.de
650 _ 7 |a Flavonoids
|2 NLM Chemicals
650 _ 7 |a Anti-oxidant
|2 Other
650 _ 7 |a Flavonoids
|2 Other
650 _ 7 |a Lipid peroxidation
|2 Other
650 _ 7 |a Lipoxygenase
|2 Other
650 _ 7 |a Prion diseases
|2 Other
650 _ 7 |a Rhenium complexes
|2 Other
650 _ 7 |a Antioxidants
|2 NLM Chemicals
650 _ 7 |a Rhenium
|0 7440-15-5
|2 NLM Chemicals
650 _ 7 |a Quercetin
|0 9IKM0I5T1E
|2 NLM Chemicals
650 _ 7 |a Hydrogen Peroxide
|0 BBX060AN9V
|2 NLM Chemicals
650 _ 7 |a 5-deoxykaempferol
|2 NLM Chemicals
650 _ 7 |a chrysin
|0 3CN01F5ZJ5
|2 NLM Chemicals
650 _ 7 |a naringenin
|0 HN5425SBF2
|2 NLM Chemicals
650 _ 7 |a PrPSc Proteins
|2 NLM Chemicals
650 _ 7 |a Organometallic Compounds
|2 NLM Chemicals
650 _ 2 |a Flavonoids: chemistry
|2 MeSH
650 _ 2 |a Humans
|2 MeSH
650 _ 2 |a Antioxidants: pharmacology
|2 MeSH
650 _ 2 |a Rhenium: chemistry
|2 MeSH
650 _ 2 |a Quercetin
|2 MeSH
650 _ 2 |a Hydrogen Peroxide
|2 MeSH
650 _ 2 |a Crystallography, X-Ray
|2 MeSH
650 _ 2 |a Flavonoids: pharmacology
|2 MeSH
650 _ 2 |a PrPSc Proteins: drug effects
|2 MeSH
650 _ 2 |a PrPSc Proteins: metabolism
|2 MeSH
650 _ 2 |a Organometallic Compounds: chemistry
|2 MeSH
650 _ 2 |a Organometallic Compounds: pharmacology
|2 MeSH
700 1 _ |a Tziouri, Vassiliki-Eleni
|b 1
700 1 _ |a Xanthopoulos, Konstantinos
|b 2
700 1 _ |a Vlachou, Maria-Eirini
|b 3
700 1 _ |a Silva-Correia, Susana
|0 P:(DE-2719)9000766
|b 4
|u dzne
700 1 _ |a Fischer, Anna-Lisa
|0 P:(DE-2719)9001954
|b 5
|u dzne
700 1 _ |a Thüne, Katrin
|0 P:(DE-2719)2811840
|b 6
|u dzne
700 1 _ |a Hatzidimitriou, Antonios
|b 7
700 1 _ |a Zerr, Inga
|0 P:(DE-2719)2000058
|b 8
|u dzne
700 1 _ |a Schmitz, Matthias
|0 P:(DE-2719)9000287
|b 9
|u dzne
700 1 _ |a Sklaviadis, Theodoros
|b 10
700 1 _ |a Hadjipavlou-Litina, Dimitra
|b 11
700 1 _ |a Papagiannopoulou, Dionysia
|0 0000-0002-7833-8744
|b 12
773 _ _ |a 10.1007/s00775-022-01986-9
|g Vol. 28, no. 2, p. 235 - 247
|0 PERI:(DE-600)1464026-0
|n 2
|p 235 - 247
|t Journal of biological inorganic chemistry
|v 28
|y 2023
|x 0949-8257
856 4 _ |y OpenAccess
|u https://pub.dzne.de/record/256473/files/DZNE-2023-00335.pdf
856 4 _ |y OpenAccess
|x pdfa
|u https://pub.dzne.de/record/256473/files/DZNE-2023-00335.pdf?subformat=pdfa
909 C O |o oai:pub.dzne.de:256473
|p openaire
|p open_access
|p VDB
|p driver
|p dnbdelivery
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 4
|6 P:(DE-2719)9000766
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 5
|6 P:(DE-2719)9001954
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 6
|6 P:(DE-2719)2811840
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 8
|6 P:(DE-2719)2000058
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 9
|6 P:(DE-2719)9000287
913 1 _ |a DE-HGF
|b Gesundheit
|l Neurodegenerative Diseases
|1 G:(DE-HGF)POF4-350
|0 G:(DE-HGF)POF4-353
|3 G:(DE-HGF)POF4
|2 G:(DE-HGF)POF4-300
|4 G:(DE-HGF)POF
|v Clinical and Health Care Research
|x 0
913 1 _ |a DE-HGF
|b Gesundheit
|l Neurodegenerative Diseases
|1 G:(DE-HGF)POF4-350
|0 G:(DE-HGF)POF4-352
|3 G:(DE-HGF)POF4
|2 G:(DE-HGF)POF4-300
|4 G:(DE-HGF)POF
|v Disease Mechanisms
|x 1
914 1 _ |y 2023
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0200
|2 StatID
|b SCOPUS
|d 2023-10-21
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0300
|2 StatID
|b Medline
|d 2023-10-21
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1050
|2 StatID
|b BIOSIS Previews
|d 2023-10-21
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1190
|2 StatID
|b Biological Abstracts
|d 2022-11-09
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0600
|2 StatID
|b Ebsco Academic Search
|d 2023-10-21
915 _ _ |a JCR
|0 StatID:(DE-HGF)0100
|2 StatID
|b J BIOL INORG CHEM : 2022
|d 2023-10-21
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1030
|2 StatID
|b Current Contents - Life Sciences
|d 2023-10-21
915 _ _ |a WoS
|0 StatID:(DE-HGF)0113
|2 StatID
|b Science Citation Index Expanded
|d 2022-11-09
915 _ _ |a DEAL Springer
|0 StatID:(DE-HGF)3002
|2 StatID
|d 2022-11-09
|w ger
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0150
|2 StatID
|b Web of Science Core Collection
|d 2023-10-21
915 _ _ |a IF < 5
|0 StatID:(DE-HGF)9900
|2 StatID
|d 2023-10-21
915 _ _ |a OpenAccess
|0 StatID:(DE-HGF)0510
|2 StatID
915 _ _ |a Peer Review
|0 StatID:(DE-HGF)0030
|2 StatID
|b ASC
|d 2023-10-21
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1150
|2 StatID
|b Current Contents - Physical, Chemical and Earth Sciences
|d 2023-10-21
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0160
|2 StatID
|b Essential Science Indicators
|d 2022-11-09
915 _ _ |a Creative Commons Attribution CC BY 4.0
|0 LIC:(DE-HGF)CCBY4
|2 HGFVOC
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0199
|2 StatID
|b Clarivate Analytics Master Journal List
|d 2023-10-21
920 1 _ |0 I:(DE-2719)1440011-1
|k AG Zerr
|l Translational Studies and Biomarker
|x 0
920 1 _ |0 I:(DE-2719)5000037
|k Ext UMG Zerr
|l Ext UMG Zerr
|x 1
920 1 _ |0 I:(DE-2719)1410002
|k AG Fischer
|l Epigenetics and Systems Medicine in Neurodegenerative Diseases
|x 2
980 _ _ |a journal
980 _ _ |a VDB
980 _ _ |a UNRESTRICTED
980 _ _ |a I:(DE-2719)1440011-1
980 _ _ |a I:(DE-2719)5000037
980 _ _ |a I:(DE-2719)1410002
980 1 _ |a FullTexts

LibraryCollectionCLSMajorCLSMinorLanguageAuthor
Marc 21